FDA Sees Safety Issue with Merck & Co., Inc. (MRK) Hepatitis Drug  
4/25/2011 8:21:00 AM

Reuters -- U.S. drug reviewers highlighted safety issues with an experimental Merck & Co hepatitis drug, including anemia and reports of psychiatric problems, in documents released on Monday.

A Food and Drug Administration advisory panel will review the potential blockbuster drug, boceprevir, at a public meeting on Wednesday. FDA staff said they generally agreed with Merck's assessment that boceprevir was effective in treating hepatitis C, a disease that destroys the liver.